Screening

Comments on the draft recommendation can be submitted through December 23, 2024.

William Grady, MD, coauthor of the ECLIPSE trial, discusses how the Shield cfDNA blood-based test compares to traditional CRC screening methods.

William Grady, MD, highlights the convenience and compliance of blood-based tests compared to colonoscopy and stool-based tests for colorectal cancer screening.

William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.

Among current smokers, 71% had never spoken a clinician about screening and among those who had quit, 75% had never had a conversation.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

ACG: Mortality associated with both early- and late-stage EO-CRC rose most significantly among young adults aged 20 to 44 years between 2000 and 2022, new research reveals.

CATD 2024: The Elecsys plasma panel also demonstrated high sensitivity and specificity for AD, building strong evidence for streamlined early disease detection.

Rebecca Hartman, MD, MHP, assistant professor of dermatology at Brigham and Women's Hospital and Harvard Medical School, reviews new point-of-care detection technology.

Dermatologist Rebecca Hartman, MD, MPH, said that reliable point-of-care screening results can help reduce unnecessary specialist referral for benign lesions.

The DermaSensor skin cancer screening device was pitted against clinical impressions of lesions suspected with high confidence to be melanoma. Results, here.

Dermatologists at high volume dermatology centers referred suspicious lesions to pathology for biopsy and diagnosis. The results were compared with DermaSensor read-outs.

More than half of US adults who had a colonoscopy in past 5 years said they wish they knew more information before their first procedure.

Nearly 40% of adults aged 45 to 50 years completed a fecal immunochemical test within 3 months, according to a large retrospective study.

Essential health screenings and immunizations are declining among US adults. A new survey identified 7 issues that help drive the reduced rates.

Your daily dose of the clinical news you may have missed.

After a false positive breast cancer screening result, women may be reluctant to participate in future screening, a topic that could benefit from the primary care touch.

Your daily dose of the clinical news you may have missed.

Even after adjusting for breast density, studies reveal a significantly greater risk for a cancer diagnosis within 2 decades. A UC Davis expert offers details.

A false positive finding on a screening mammogram is fairly common, according to UC Davis biostatistician Diana Miglioretti, PhD. Here's why.

The group of women least likely to return for a regular preventive screening mammogram after a false positive result surprised this primary investigator.

After a false positive outcome on screening mammography, a short interval call back for repeat imaging was a significant deterrent to future screening.

Increases in CRC screening were higher in high socioeconomic status and metropolitan areas, according to a new large cohort study.

Cologuard Plus bests its previous iteration and demonstrates greater sensitivity and specificity for any CRC relative to fecal immunochemical tests.

Having a PCP is linked to higher rates of screening colonoscopy and improved overall survival. Review these 12 facts about CRC and share them with your patients.

Breast cancer will claim the lives of more than 42 000 women in 2024. The primary care clinician's role as advocate for screening mammography can not be overemphasized.

The decline in cancer diagnoses during the COVID-19 shutdown in 2020 did not lead to an expected compensatory increase in diagnoses in 2021, according to NCI researchers.

Those least likely to schedule further screening mammograms had received a false-positive with recommendation for follow-up after only a short interval.

Your daily dose of the clinical news you may have missed.